Related Experiment Video
Updated: Apr 29, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
Published on: December 4, 2016
A macrocyclic chelator with unprecedented Th⁴⁺ affinity
Tiffany A Pham1, Jide Xu, Kenneth N Raymond
1Department of Chemistry, University of California, Berkeley , Berkeley, California 94720-1460, United States.
A new octadentate ligand efficiently chelates thorium(4+), forming a highly stable complex. This rapid thorium chelation shows promise for radiotherapeutic applications.
Area of Science:
- Coordination Chemistry
- Radiochemistry
- Materials Science
Background:
- Thorium(4+) chelation is crucial for radiotherapeutic applications.
- Existing ligands like DOTA and DTPA have limitations in thorium chelation efficiency and stability.
- Development of novel chelating agents is needed for improved therapeutic outcomes.
Purpose of the Study:
- To synthesize and characterize a novel macrocyclic octadentate ligand for thorium(4+) chelation.
- To evaluate the kinetic and thermodynamic properties of the thorium-ligand complex.
- To assess the potential of this new ligand system in radiotherapeutic applications.
Main Methods:
- Synthesis of a novel macrocyclic octadentate ligand with terephthalamide units.
- Structural characterization of the thorium complex using X-ray diffraction.
- Solution studies including kinetic experiments and spectrophotometric titrations.
- Dye displacement assays to compare chelation rates with established ligands.
Main Results:
- The novel ligand demonstrated rapid chelation of thorium(4+).
- The thorium complex exhibited exceptional thermodynamic stability, with a formation constant of 10(54).
- The new ligand significantly outperformed DOTA and DTPA in terms of chelation kinetics.
Conclusions:
- The synthesized macrocyclic octadentate ligand is a highly effective chelator for thorium(4+).
- The exceptional stability and rapid chelation kinetics suggest significant potential for radiotherapeutic applications.
- This ligand represents a promising advancement in the field of targeted alpha therapy and related nuclear medicine applications.
More Related Videos
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
10:54Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry
Published on: February 4, 2017